BIOADAPTIVES, INC. (BDPT) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-05-05

Key Insights

Director Mark P. Frissora received 4,808 shares of Series D Convertible Preferred Stock on 05/01/2026 as board compensation, demonstrating continued director engagement and alignment with the company.
The preferred shares convert to 480,800 common shares at a 100:1 ratio but are subject to a 4.9% beneficial ownership limitation, indicating anti-dilution protections are in place for the company.
Conversion is restricted for six months from issuance (until 11/01/2026) except in liquidation events, suggesting the company has structured vesting to retain insider commitment through mid-November 2026.
The preferred shares carry 100 votes per share without ownership limitations for voting purposes, granting Frissora significant voting power (480,800 votes) despite the conversion cap.

Want the newest filings?

This analysis covers the filing from 2026-05-05. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-03-03

The reporting person, Mark P. Frissora, has acquired 2,578 shares of Series D Convertible Preferred Stock of BioAdaptives, Inc. (BDPT), which are convertible into 257,800 shares of common stock.
The Series D Convertible Preferred Stock was issued as compensation for Frissora's board services, indicating his continued involvement and commitment to the company.
The convertible preferred shares have a 4.9% beneficial ownership limitation, which may limit Frissora's ability to exercise full control over the company.

Other reports for BIOADAPTIVES, INC.

Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.